Hepatitis B virus (HBV) is a noncytopathic virus, and the clinical outcome of HBV infection is determined by the quality and strength of the host immune response to the virus. T-cell responses are weak or undetectable in patients with chronic HBV infection. Mechanisms associated with this treatment response are not understood. Serial analysis of HBV-specific CD4+ T-cell reactivity was performed during 48 weeks of therapy with ADV and correlated with treatment outcome for 19 HBV-positive patients receiving ADV (n = 13) or the placebo (n = 6). We tested T-cell reactivity to HBV at seven protocol time points by proliferation, cytokine production, and enzyme-linked immunospot assays. A panel of serum cytokines was quantitated by cytokine bead array. ADV-treated patients showed increased CD4+ T-cell responses to HBV and lower serum levels of cytokines compared to those of placebo-treated patients. Enhanced CD4+ T-cell reactivity to HBV, which peaked at treatment week 16, was confined to a subgroup of ADV-treated patients who achieved greater viral suppression (5.3 ± 0.3 log10 copies/ml [mean ± standard error of the mean (SEM)]) serum viremia reduction who remained HBeAg positive or to patients receiving the placebo. In conclusion, T-cell reactivity to HBV increases in a proportion of ADV-treated patients and is associated with greater suppression of HBV replication and HBeAg loss.

Based on this understanding of HBV-host interactions, the treatment strategy for chronic hepatitis B is direct suppression of HBV replication and enhancement of the host's immune-reactivity to the virus to achieve sustained viral control and remission of liver disease. Currently available treatments with IFN-α or oral antivirals are effective for only a small proportion of patients (9, 12, 27). The underlying mechanisms that differentiate treatment responders from nonresponders, particularly the role of antiviral immune responses, are poorly understood. Adefovir dipivoxil (ADV) is an oral nucleotide analogue of AMP, which blocks HBV DNA synthesis of wild-type (HBeAg+) and precore mutant HBV (HBeAg−) as well as lamivudine-resistant HBV mutants (6, 26). A randomized, double-blind, placebo-controlled trial established that 48 weeks of treatment with ADV significantly reduces HBV DNA, normalizes liver transaminases, and increases the rate of HBeAg seroconversion in patients with HBeAg+ chronic hepatitis B (13).

The aims of this investigation were to prospectively analyze the changes in HBV-specific CD4+ T-cell reactivity during ADV treatment in patients with HBeAg+ chronic hepatitis B and to correlate these changes with treatment outcome.

**MATERIALS AND METHODS**

**Patients and study design.** The investigation of T-cell reactivity was conducted as a substudy to a phase III trial comparing treatment with ADV versus that with a placebo in HBeAg+ patients with chronic hepatitis B (study number GS-98-
313 ADV THERAPY AND T-CELL REACTIVITY IN CHRONIC HBV

There is a significant difference in ALT at TW48 between group 1 and group 3 (P = 0.05). The data are shown as means ± standard deviations.

In vitro cytokine production and enzyme-linked immunosorbent (ELISPOT) assay. To analyze HBV-specific cytokine production, PBMC (3 × 10^6/ml) were resuspended in RPMI plus 10% AB serum, and 100 μl was added per well in a 96-well tissue culture plate. PBMC were incubated in quadruplicate for 6 days in the presence or absence of HBcAg (1 μg/ml; American Research Products, Belmont, MA); tetanus toxoid, a positive control as a recall antigen (0.5 μg/ml; Connaught Laboratories, Ontario, Canada); and phytohemagglutinin. In the supernatants from PBMC cultures, the heparinized blood samples from the two United Kingdom centers were processed at the Institute of Hepatology, UCL, with T-cell proliferation and in vitro cytokine production tested with fresh cells, and the remaining PBMC were cryopreserved.

**Procedures.** PBMC were isolated from heparinized blood by density gradient centrifugation with Lymphoprep (Nygard, Oslo, Norway). Part of the PBMC were cryopreserved at 5 × 10^6 cells/ml in heat-inactivated fetal bovine serum (Invitrogen, Paisley, United Kingdom) containing 10% dimethyl sulfoxide (Sigma, Poole, United Kingdom). The aliquots were placed overnight at –80°C in a cryogenic vessel (Merck, Poole, United Kingdom) containing isopentane and subsequently transferred into liquid nitrogen.

**T-cell proliferation assay.** All T-cell proliferation tests were performed with freshly isolated PBMC as described previously (10, 24). The cells were resuspended at a concentration of 2 × 10^6/ml in buffered RPMI, supplemented with 10% human AB serum (Gemini Bio-Products, Sacramento, CA), and 100 μl was added well in a 96-well, flat-bottom plate (Merck, Poole, United Kingdom). The antigens added to quadruplicate wells were the following: recombinant HBcAg (rHBcAg) (1 μg/ml; American Research Products, Belmont, MA); tetanus toxoid, a positive control as a recall antigen (0.5 μg/ml; Connaught Laboratories, Ontario, Canada); and phytohemagglutinin (1 μg/ml; Sigma–Aldrich, Poole, United Kingdom). After 6 days, the cells were pulsed with 0.5 μCi/well [3H]thymidine and its incorporation into DNA was measured by a beta counter. A stimulation index was calculated by dividing the mean counts per minute of the replicates of antigen-stimulated PBMC by those of PBMC incubated in medium only. A stimulation index greater than the mean plus 3 standard deviations of control subjects was considered a significant response. As the proliferation assays were performed at each study center, the cutoff was determined separately at each center by testing PBMC from 15 to 20 control subjects.

**TABLE 1. Characteristic parameters at baseline**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value for group given:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adefovir</td>
</tr>
<tr>
<td></td>
<td>(n = 13)</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>39.2 ± 12.8</td>
</tr>
<tr>
<td>Gender</td>
<td>11:2</td>
</tr>
<tr>
<td>Racial group</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>10</td>
</tr>
<tr>
<td>Black</td>
<td>1</td>
</tr>
<tr>
<td>Asian</td>
<td>2</td>
</tr>
<tr>
<td>ALT (IU/ml)*</td>
<td>128.3 ± 63.4</td>
</tr>
<tr>
<td>HBV DNA (log_{10} copies/ml)*</td>
<td>8.3 ± 0.6</td>
</tr>
<tr>
<td>HBV genotype</td>
<td>(n = 13)</td>
</tr>
<tr>
<td>A</td>
<td>5</td>
</tr>
<tr>
<td>C</td>
<td>1</td>
</tr>
<tr>
<td>D</td>
<td>5</td>
</tr>
<tr>
<td>E</td>
<td>1</td>
</tr>
<tr>
<td>G</td>
<td>2</td>
</tr>
<tr>
<td>Received previous IFN-α treatment (n = 13)</td>
<td>3</td>
</tr>
</tbody>
</table>

* The data are shown as means ± standard deviations.

**TABLE 2. Comparison of virological parameters in all patients at baseline with those at TW48**

<table>
<thead>
<tr>
<th>Group</th>
<th>No. of patients who were treated with:</th>
<th>Values for parameter at the indicated time point</th>
<th>No. of patients with indicated status at TW48</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ADV, 30 mg/day*</td>
<td>ADV, 10 mg/day</td>
<td>Placebo</td>
</tr>
<tr>
<td></td>
<td>Baseline</td>
<td>TW48</td>
<td>△</td>
</tr>
<tr>
<td>1 (n = 7)</td>
<td>4</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>2 (n = 6)</td>
<td>3</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>3 (n = 6)</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
</tbody>
</table>

* The data are shown as means ± standard deviations.

**No. of patients who were treated with**: ADV, 30 mg/day.*

* According to the phase I trial protocol, patients receiving ADV were randomized to receive either a 30-mg or a 10-mg dose and the two columns reflect the ADV treatment groups per study protocol. In the present T-cell study, there was no statistical difference between the subgroups of patients receiving 10 versus 30 mg of ADV/day.

**Values for parameter at the indicated time point**: HBV DNA (log_{10} copies/ml)*

* There is no significant difference in ALT at baseline between groups. P values were 0.78 for group 1 versus group 2, 0.063 for group 1 versus group 3, and 0.128 for group 2 versus group 3.

**No. of patients with indicated status at TW48**: HBeAg -

* There is a significant difference in ALT at TW48 between group 1 and group 3 (P = 0.032), but not group 1 and group 2 (P = 0.317) or group 2 and group 3 (P = 0.11).
was added for 2 h. After being washed, the plates were incubated with 100 µl streptavidin-alkaline phosphatase conjugate (Mabtech). The enzyme reaction was developed with freshly prepared nitroblue tetrazolium chloride-bromo-chloro-indolyl-phosphate toluidine salt (Roche Diagnostics, Lewes, England). The spots were counted with an ELISPOT reader (AID, Strassberg, Germany). The number of specific spot-forming cells per 1 × 10^6 PBMC was determined as the mean number of spots in the presence of an antigen minus the mean number of spots in the wells with medium only. The cutoff for significant response was defined as the mean plus 2 standard deviations from testing 10 subjects without HBV exposure. Repeat testing of positive samples with T-cell proliferation and ELISPOT assays, using immunomagnetic depletion of CD4 T cells, confirmed that the responses to rHBcAg and tetanus represent CD4 T-cell reactivity.

**Determination of serum cytokine profiles.** The serum levels of IFN-γ, IL-2, IL-5, IL-8, IL-10, IL-12p70, Fas ligand, and IP-10 were quantitated for each patient at baseline, TW16, and TW48 by using the cytometric bead array assay (BD Biosciences, Oxford, United Kingdom) in accordance with the manufacturer's instructions. This assay employs beads with distinct fluorescence intensities and specificities for a single cytokine. The beads were analyzed using a flow cytometer (FACS array; BD Biosciences) to measure the tested cytokines in a single sample. The concentration of all eight cytokines in each well was calculated using BD FCAP Array software (BD Biosciences, Oxford, United Kingdom). All ELISPOT assays and cytokine measurements were performed at the Institute of Hepatology, UCL, without knowledge of patient treatment assignments and ALT and serum HBV DNA levels.

**Hepatitis serology.** Serum HBV markers (HBsAg, anti-HBs, HBeAg, and anti-HBe), anti-HCV, anti-HDV, and antibody to human immunodeficiency virus were tested by enzyme immunoassays (Abbott Laboratories, Diasorin, and Covance Laboratories). Serum HBV DNA levels were quantitated by Amplicor Monitor PCR (Roche Molecular Systems), with a lower limit of detection (LLD) of 400 copies/ml.

**Statistical analyses.** Differences in T-cell responses between patient groups or time points were tested by the Fisher exact test or the Wilcoxon signed-rank test. Correlations were tested by the nonparametric Spearman's rank test. We normalized the cytokine levels for each cytokine and time point, i.e., the cytokine level relative to the average level of that cytokine at that time point. The hierarchical clustering method of the normalized values was used to find whether different cytokine profiles cluster together. This method allowed combining the normalized values of clustered cytokines and analyzing them together at baseline and during therapy. The statistical significance of differences in normalized

**FIG. 1.** Comparison of CD4 T-cell reactivity to HBcAg in patients receiving ADV or the placebo. *, there was a significant increase in the frequencies of IFN-γ-producing CD4 T cells at TW16 compared to baseline values for ADV-treated patients (P = 0.03). ***, at TW40 and TW48, patients receiving ADV had significantly higher frequencies of IFN-γ-producing CD4 T cells than did patients receiving placebos (P = 0.03). The bars represent means ± SEMs.

**FIG. 2.** Relationship between serum HBV DNA levels and the frequency of virus-specific CD4 T cells during the study period for the three groups of patients presented in Table 2. *, patients in group 1 had significantly lower HBV DNA levels at TW48 than did patients in groups 2 (P = 0.011) and 3 (P = 0.003). **, patients in group 2 had significantly lower HBV DNA levels at TW48 than did patients in group 3 (P = 0.028). The bars represent the means ± SEMs for the frequency of HBV-specific CD4 T cells. Error bars indicate standard deviations.
were no significant changes in the placebo group ($P = 0.03$). Furthermore, at TW40 and TW48, ADV-treated patients in comparison with the baseline value ($P < 0.05$). There were no significant differences in serum HBV DNA levels at baseline between these three groups of patients (the $P$ value was >0.1) (Table 2); however, there were significant differences in serum HBV DNA levels at TW48 (the $P$ values were 0.011 for group 1 versus group 2 and 0.028 for group 2 versus group 3) (Fig. 2).

The analysis of T-cell proliferative responses in these three subgroups revealed that T-cell proliferation to HBcAg occurred more frequently in patients with a greater viral load reduction and HBeAg loss, i.e., more frequently in group 1 (18 of 52 tests [35%]) than in group 2 (7 of 44 tests [16%]; $P = 0.03$) (Fig. 3). There was no significant difference in T-cell proliferative responses between HBeAg$^+$ patients with lower viral suppression levels (group 2, 12 of 43 tests [28%]) in comparison with those of group 3 ($P = 0.18$). The frequency of HBcAg-specific, IFN-$\gamma$-producing CD4$^+$ T cells reached the highest level at TW16, particularly in group 1, compared with the baseline values ($P = 0.06$ [Fig. 2]). The peak increase of virus-specific T cells at TW16 in group 1 patients was followed by a further reduction in viremia (particularly at TW40 and TW48), which was not observed in group 2 (Fig. 2). PBMC from all patients showed good proliferative responses in the control assays (data not shown).

There were marked differences in the in vitro PBMC production of IFN-$\gamma$ in response to HBeAg between the three groups. The IFN-$\gamma$ levels in the supernatants of PBMC cultured with HBeAg of group 1 patients were significantly higher than those of group 3 at baseline ($P = 0.05$) (Table 3). IFN-$\gamma$ production was also higher in group 1 patients at TW4, TW8, and TW16 than in group 2 or group 3 patients, although these differences were not significant. The quantitation of the production of IL-10 in the same supernatants showed no significant differences between patients in any of the three groups or between those receiving ADV or the placebo.

**RESULTS**

The 13 patients randomized to receive ADV completed 48 weeks of treatment, and serum HBV DNA levels decreased by 4.34 ± 0.36 log$_{10}$ copies/ml (mean ± standard errors of the mean [SEM]) in comparison to the baseline value. The six patients receiving the placebo had minor changes in serum HBV DNA levels: a decrease of 0.72 ± 0.44 log$_{10}$ copies/ml (mean ± SEM) at TW48 compared with the baseline value. The loss of HBeAg was observed in 7 of 13 (54%) ADV-treated patients, and 4 of these 7 seroconverted to anti-HBe (Table 2).

**Antiviral CD4$^+$ T-cell reactivity may increase during adefovir treatment.** During the study period, T-cell proliferative responses to HBcAg were detected more frequently in ADV-treated patients (30 of 95 tests [32%]) than in placebo-treated patients (5 of 48 tests [10%]; $P = 0.02$). At baseline, there was no significant difference for HBV core-specific CD4$^+$ T cells (producing IFN-$\gamma$) in ADV-treated patients and in those receiving the placebo (Fig. 1). The frequency of HBV-specific CD4$^+$ T cells increased significantly in the ADV group at TW16 in comparison with the baseline value ($P < 0.05$). There were no significant changes in the placebo group ($P = 0.35$) (Fig. 1). Furthermore, at TW40 and TW48, ADV-treated patients maintained significantly greater frequencies of virus-specific T cells than did placebo-treated patients ($P = 0.03$).

**Relationship between viral suppression and T-cell responses.** Based on HBeAg status and serum HBV DNA levels at TW48, three subgroups of patients were identified (Table 2). Seven ADV-treated patients lost HBeAg and showed a reduction in viral load of 5.3 ± 0.4 log$_{10}$ copies/ml (mean ± SEM); in five of seven patients, serum HBV DNA was below the LLD (group 1). The other 12 patients remained HBeAg$^+$; of these, 6 ADV-treated patients had HBV DNA reductions of 3.4 ± 0.2 log$_{10}$ copies/ml (mean ± SEM) (only 1 of 6 had HBV DNA level below the LLD [group 2]), while 6 patients who received the placebo showed smaller changes in HBV-DNA level (0.7 ± 0.4 log$_{10}$ copies/ml [mean ± SEM] [group 3]). There were no significant differences in serum HBV DNA levels at baseline between these three groups of patients (the $P$ value was >0.1) (Table 2); however, there were significant differences in serum HBV DNA levels at TW48 (the $P$ values were 0.011 for group 1 versus group 2 and 0.028 for group 2 versus group 3) (Fig. 2).

The IFN-$\gamma$ production index was calculated at each time point by dividing the mean pg/ml IFN-$\gamma$ production of four replicates of HBcAg-stimulated PBMC by that of the control cultures (PBMC incubated in medium only). Group 1 patients had significantly higher IFN-$\gamma$ production values at baseline compared to those of group 3 ($P = 0.05$), but not to those of group 2 ($P = 0.1$). All data are shown as means ± standard deviations.

**TABLE 3. In vitro IFN-$\gamma$ production after stimulation with rHBcAg**

<table>
<thead>
<tr>
<th>Group</th>
<th>IFN-$\gamma$ production index$^a$ at:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BL</td>
</tr>
<tr>
<td>1</td>
<td>$99.2$ ± $29.3$</td>
</tr>
<tr>
<td>2</td>
<td>$26.2$ ± $53.6$</td>
</tr>
<tr>
<td>3</td>
<td>$20.3$ ± $5.0$</td>
</tr>
</tbody>
</table>

$^a$ The IFN-$\gamma$ production index was calculated at each time point by dividing the mean pg/ml IFN-$\gamma$ production of four replicates of HBcAg-stimulated PBMC by that of the control cultures (PBMC incubated in medium only). Group 1 patients had significantly higher IFN-$\gamma$ production values at baseline compared to those of group 3 ($P = 0.05$), but not to those of group 2 ($P = 0.1$). All data are shown as means ± standard deviations.
To gain information about the relationship between viral load reduction during ADV treatment, HBeAg loss, and the frequencies of HBV-specific T cells, we analyzed the time course of these events in individual patients. A reduction in serum HBV DNA to around 3 log_{10} copies/ml was associated with increased IFN-γ-producing CD4^+ T cells at different time points in individual cases, with the highest frequency observed usually at TW16 or TW24 (Fig. 4a and b). The increase of
IFN-γ-producing CD4⁺ T cells preceded or coincided with the loss of HBeAg. Importantly, the loss of HBeAg was not associated with ALT flare. Patients in group 2 showed no significant changes in HBV core-specific CD4⁺ T-cell reactivity during the course of ADV treatment (Fig. 4c).

Serum cytokine profiles during adefovir treatment. There was no correlation between any of the cytokine levels at baseline (for all patients studied or for ADV and placebo groups separately) and baseline HBV-DNA or ALT levels. Although baseline ALT levels were higher for the ADV group than for the placebo group (Table 1), serum cytokine levels did not differ, except for IL-10, which was significantly higher for patients who received the placebo than for patients who received ADV (51 ± 19 pg/ml versus 32 ± 13 [mean ± SEM]; P = 0.028). A highly significant correlation was found between baseline serum levels for IL-12p70 and IFN-γ (r = 0.801; P < 0.001), IL-12p70 and IL-2 (r = 0.958; P < 0.001), and IFN-γ and IL-2 (r = 0.679; P = 0.005). The hierarchical clustering analysis showed that the normalized levels of six of eight measured cytokines (IFN-γ, IL-2, IL-5, IL-10, IL-12p70, and Fas ligand, but not IP-10 and IL-8) strongly intercorrelated (r > 0.7; P < 0.001). The combined normalized values for the six clustered cytokines were higher for the placebo group than for patients randomized to ADV (P < 0.001) and were also higher when we compared only IL-12p70, IFN-γ, and IL-2 (P = 0.005) (Fig. 5). When we compared the subgroups treated with ADV, baseline cytokine levels showed a trend to be higher for group 1 than for group 2 (Fig. 5).

Interestingly, the difference in cytokine levels between the ADV and placebo groups became more pronounced at TW16, with significantly lower absolute values for IFN-γ, IL-10, IL-12p70, Fas ligand, IL-2, and IL-5 for ADV-treated patients than those for patients in the placebo group. This result was also found when cluster analysis, including all clustered cytokines (except IP-10 and IL-8) or only IL-12p70, IL-2, and IFN-γ, was used (Fig. 5). At TW16, there was no difference between the absolute values, or with the cluster analysis, between patients in groups 1 and 2.

DISCUSSION

This longitudinal, placebo-controlled study demonstrates that the suppression of HBV replication with ADV significantly enhances virus-specific CD4⁺ T-cell reactivity with IFN-γ production in some patients with HBeAg⁺ chronic hepatitis B. T-cell reactivity increased only in a proportion of ADV-treated patients and may have contributed to a greater suppression of HBV replication with HBeAg loss in this subgroup. Thus, the present study indicates that overcoming T-cell hyporesponsiveness to HBV, which is characteristic for patients with high viremia levels (4), is an important component for achieving HBe seroconversion with oral antiviral therapy. Studies of adaptive immunity to HBV have established a correlation between strong proliferative responses of CD4⁺ T cells and spontaneous resolution of HBV infection (4). The critical role of host immune response in the resolution of chronic HBV infection is best demonstrated by HBsAg⁺ recipients of bone marrow transplantation who received marrow from donors with natural immunity to HBV. The transplantation of a healthy immune system, including T cells reactive to HBV nucleocapsid protein, led to the resolution of chronic hepatitis B with anti-HBs seroconversion (10).
The present study reveals that patients with chronic hepatitis B, who cleared HBeAg within 48 weeks of ADV treatment, are characterized by higher CD4+ T-cell reactivity to HBV. These patients showed higher IFN-γ production at baseline and an increase of the frequency of HBcAg-specific, IFN-γ-producing CD4+ T cells upon treatment. In contrast, the measurement of serum cytokines appeared to reflect the nonspecific immune responses and showed the opposite profile to HBV-specific T-cell reactivity, as detected by proliferation, ELISPOT, and HBcAg-specific IFN-γ production assays. HBV suppression with ADV decreased serum cytokine levels at TW16, in contrast with the increased virus-specific reactivity of CD4+ T cells at the same time point.

HBeAg is believed to induce T-cell tolerance, thus promoting chronic HBV persistence (18). However, the enhanced CD4+ T-cell reactivity in group 1 patients usually preceded HBeAg loss, suggesting that T-cell hyporesponsiveness may be associated with high viral load, while HBeAg loss during treatment may be mainly a result of enhanced T-cell function. Combined monitoring of viral load decline and the T-cell reactivity to HBV during antiviral treatment would provide a better understanding of the mechanisms and likelihood of treatment response. Future studies on adaptive immunity during therapy will need to clarify the interplay between HBV-specific CD4+ and CD8+ T cells (18) and the relative impact of viral suppression for improved dendritic cell function (18) and/or HBV-specific T-cell responses. Importantly, the production of anti-HBe is strictly dependent on CD4+ T cells and anti-HBe titers are higher in patients with raised ALT levels (16, 19). The role of CD4+ T cells in promoting humoral immunity to HBV, in particular anti-HBe production, during antiviral therapy deserves further investigation.

The enhanced frequency of virus-specific, IFN-γ-producing T cells in patients in group 1 was not associated with ALT
flares, thus emphasizing the involvement of noncytolytic antiviral mechanisms. Moreover, the serum levels of nonspecific cytokines for these patients were lower than those for patients receiving the placebo. A large body of evidence has established that HBV replication can be controlled efficiently by IFN-γ released from HBV-specific T cells, resulting in intracellular virus inactivation without killing infected hepatocytes (8). In vitro experiments have demonstrated directly that IFN-γ secreted by T cells from patients with chronic hepatitis B effectively inhibits HBV transcription and replication in hepatocytes without cell lysis (25).

The baseline levels of virus-specific IFN-γ production were significantly higher for group 1 than for group 2 or group 3, indicating that the T cells in patients from group 1 are more “immunoreactive” with the production of IFN-γ, which may exert noncytolytic control of HBV replication in addition to the antiviral effect of adefovir. Different patterns of T-cell reactivity to HBV antigens have been observed during lamivudine treatment of chronic hepatitis B. In HBsAg+ patients with markedly raised ALT levels, a temporal association was observed between serum HBV DNA decline and increased CD4+ T-cell reactivity (1, 2). Such a marked increase of T-cell reactivity during lamivudine treatment, however, is not universal. We have previously shown that HBsAg+ patients with low ALT levels, who had failed previous interferon therapy, did not show significant changes in CD4+ T-cell proliferation to rHBcAg during lamivudine treatment (14). The latter subset corresponds to patients in group 2 in the present study, who had a moderate decrease in serum HBV DNA but showed no significant increase in T-cell reactivity to HBV and remained HBsAg+ despite undergoing ADV treatment as patients in group 1.

Chronic hepatitis B is a heterogeneous disease, requiring more individualized treatment regimens. For example, a combination of ADV plus DNA vaccine has shown an additive antiviral effect in the duck HBV infection model (11); in chronically infected woodchucks, prolonged antiviral treatment, followed by therapeutic immunization, induced HBsAg clearance (17). The present study suggests that in a subset of ADV-treated patients with enhanced T-cell reactivity upon treatment, therapeutic vaccination may boost T-cell responses and increase HBsAg clearance. Instead, patients with a moderate HBV DNA reduction and T-cell hyporeactivity may require prolonged therapy or additional antiviral compounds for greater suppression of HBV replication and to prevent drug resistance.

ACKNOWLEDGMENTS

The study was supported by a research grant from Gilead Sciences, Foster City, CA.

The following persons contributed to the organization or provided technical support for the study: Michael Manns (Hanover, Germany); Carmela Cursaro (Bologna, Italy); Alexander Smith (Manchester, United Kingdom); Mario Rizzetto (Turin, Italy); Alexander Thermet (Lyon, France); and Shelly Xiong, Craig P. James, Anant Jain, and Craig Gibbs (Gilead Sciences, Foster City, CA).

REFERENCES


